The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a huge mover today! About 1.24M shares traded hands. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has declined 28.97% since April 4, 2016 and is downtrending. It has underperformed by 30.06% the S&P500.
The move comes after 6 months positive chart setup for the $836.59 million company. It was reported on Nov, 4 by Barchart.com. We have $7.87 PT which if reached, will make NASDAQ:FOLD worth $225.88M more.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage
Out of 7 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Amicus Therapeutics has been the topic of 11 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Chardan Capital Markets downgraded Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Wednesday, September 16. Chardan Capital Markets has “Neutral” rating and $17 price target. Leerink Swann maintained the stock with “Buy” rating in Monday, August 31 report. The rating was upgraded by Chardan Capital Markets on Monday, October 5 to “Buy”. The firm has “Buy” rating given on Tuesday, March 8 by Janney Capital. The rating was downgraded by Zacks on Tuesday, August 18 to “Buy”. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Neutral” rating given on Wednesday, March 30 by Goldman Sachs. As per Wednesday, May 18, the company rating was initiated by Bank of America. The company was maintained on Tuesday, September 1 by Cowen & Co. The rating was maintained by JP Morgan with “Overweight” on Tuesday, September 8. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Outperform” rating by Leerink Swann on Monday, October 5.
According to Zacks Investment Research, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.”
Insitutional Activity: The institutional sentiment increased to 1.64 in 2016 Q2. Its up 0.71, from 0.93 in 2016Q1. The ratio increased, as 20 funds sold all Amicus Therapeutics, Inc. shares owned while 25 reduced positions. 22 funds bought stakes while 52 increased positions. They now own 136.20 million shares or 2.45% more from 132.95 million shares in 2016Q1.
Moreover, Northern Trust Corp has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 1.44 million shares. Jpmorgan Chase And Communications accumulated 0% or 992,689 shares. Qs Invsts Limited Liability Com accumulated 0.01% or 183,324 shares. Blackrock Inc has 0% invested in the company for 26,443 shares. Highbridge Mgmt Ltd Liability Corp accumulated 246,236 shares or 0.02% of the stock. Pacad holds 78,286 shares or 0.06% of its portfolio. Moreover, State Board Of Administration Of Florida Retirement has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 55,248 shares. New York State Common Retirement Fund last reported 150,028 shares in the company. The Minnesota-based Ameriprise Financial has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Redmile Grp Inc Limited Com has 11.11 million shares for 5.79% of their US portfolio. Morgan Stanley owns 58,148 shares or 0% of their US portfolio. Rs Investment Mngmt Co Ltd, a California-based fund reported 3.43 million shares. Ubs Oconnor Llc has invested 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Blackrock Inv Mgmt Ltd Liability Co has 472,055 shares for 0% of their US portfolio. Sectoral Asset Mgmt Incorporated accumulated 2.7% or 4.79 million shares.
Insider Transactions: Since June 2, 2016, the stock had 2 insider purchases, and 8 insider sales for $7.99 million net activity. Do Hung also sold $175,000 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares. 66,300 shares with value of $477,360 were bought by Redmile Group – LLC on Friday, June 3. $146,412 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Barth Jay on Wednesday, July 27. On Thursday, August 25 PERCEPTIVE ADVISORS LLC sold $7.49M worth of the stock or 1.10 million shares. The insider Rosenberg Ellen bought 15,000 shares worth $115,050. Another trade for 20,500 shares valued at $164,075 was made by Baird William D III on Tuesday, September 20.
Another recent and important Amicus Therapeutics, Inc. (NASDAQ:FOLD) news was published by Medgadget.com which published an article titled: “Amicus Therapeutics, Inc Clinical Trial Review, Market Growth, Medical Trends …” on November 03, 2016.
FOLD Company Profile
Amicus Therapeutics, Inc., incorporated on February 4, 2002, is a biopharmaceutical company. The Firm is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. The Company’s lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). The Firm has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. The Firm is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa (EB). It has also initiated a clinical study in patients with Pompe disease, another LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with a pharmacological chaperone, AT2221, to improve activity and stability.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.